Burden of hospitalization of patients with Candida and Aspergillus infections in Australia  by Slavin, Monica et al.
International Journal of Infectious Diseases 8 (2004) 111—120
Burden of hospitalization of patients with
Candida and Aspergillus infections in Australia
Monica Slavina, John Fastenaub, Isaya Sukaromc, Panagiotis Mavrosb,
Steven Crowleyd, William C. Gerthb,*
a Infectious Diseases, Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia
b Outcomes Research, Merck & Co., Inc., One Merck Drive, PO Box 100, Whitehouse Station,
NJ 08889, USA
c College of Pharmacy, Rutgers University, New Brunswick, NJ, USA
d Merck Sharp & Dohme, Center for Health Program Evaluation, The University of Melbourne,
South Granville, NSW 2142, Australia
Received 5 August 2002 ; received in revised form 14 April 2003; accepted 2 May 2003
Corresponding Editor: Michael Whitby, Brisbane, Australia
KEYWORDS
Aspergillosis;
Australia;
Candidiasis;
Cost of illness;
Hospitalization;
Length of stay;
Mortality;
Mycoses
Summary Objectives: This study examined the burden of hospitalization of patients
with Aspergillus and Candida infections in Australia from 1995 to 1999.
Methods: Data were extracted from the National Hospital Morbidity Database. A
hospitalization with an aspergillosis diagnosis was deﬁned as any discharge with a
diagnosis of aspergillosis. A hospitalization with a candidiasis diagnosis was deﬁned as
any discharge with a diagnosis of disseminated, invasive, or non-invasive candidiasis.
Outcome measures included number of hospitalizations, length of stay (LOS), cost
(AUS$), and mortality.
Results: 4583 hospitalizations with an aspergillosis diagnosis and 57,758 hospital-
izations with a candidiasis diagnosis were identiﬁed. These hospitalizations were as-
sociated with a total of 813,398 hospital days, AUS$563 million in cost, and 4967
in-hospital deaths during the study period. The mean LOS for a hospitalization with an
aspergillosis diagnosis was 12 days, cost AUS$9,334, and was associated with 8% mor-
tality. For disseminated, invasive, and non-invasive candidiasis, the respective mean
LOS were 31, 17, and 12 days; costs were AUS$33,274, AUS$12,954, and AUS$7,694;
and mortality was 26%, 9%, and 8%.
Conclusions: Hospitalizations with diagnoses for fungal infections were associated
with lengthy hospital stays, high costs, and high mortality.
© 2003 International Society for Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
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Introduction
As populations of immunocompromised and severely
ill patients have grown over the past several
decades, so too have the frequencies and types of
life-threatening, opportunistic fungal infections.1—5
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Invasive and/or disseminated fungal infections
have proven to be a signiﬁcant and growing cause
of morbidity and mortality in immunocompromised
patients, such as those suffering from AIDS and
cancer.2,6 The two fungal pathogens causing the
majority of infections, Aspergillus and Candida,7,8
have seen reported increases in incidence of 3 to
20 and 3.5 to 14 times, respectively, during the
past two decades.9—11 In particular, there has been
an increase in the number of infections acquired
during the course of hospitalization; reports have
estimated a doubling in the rate of invasive fun-
gal infections during the 1980s in US hospitals.12
Candida species were reported in the seminal
Surveillance and Control of Pathogens of Epidemi-
ologic Importance (SCOPE) study to be the fourth
most commonly isolated nosocomial bloodstream
pathogen, fungal and otherwise, in the United
States from 1995—1998.13
The burden of these mycotic infections is high in
terms of incidence and mortality; however, these
measures vary considerably by cause or clinical
manifestation of infection as well as characteristics
of at-risk populations. For example, the incidence
of invasive aspergillosis in heart and renal trans-
plantation patients ranges from 0.5% to 10%,11
while the incidence of oropharyngeal candidiasis
has been reported to be as high as 90% in AIDS
patients.14,15 Aspergillosis has been associated
with mortality of over 95%,11 while the mortality
associated with Candida bloodstream infections
has been reported to be between 38%—75% for a
wide range of patient groups.2,9,13,16
Fungal infections have been shown to increase
the length of hospital stay (LOS) and the cost of
care.9,17—19 Previous studies examining LOS asso-
ciated with bloodstream infections have found a
22 to 34 day increase for candidemic patients ver-
sus controls depending upon characteristics of the
host.9,17,18 The overall cost of hospitalization ass-
ociatedwith candidemia was estimated in one study
conducted in the United States to be US$34,123 to
44,536 per case, for a total of US$216 to 281 million
per year.18 Similarly, in another study conducted in
the United States, hospitalizations with aspergillo-
sis as a secondary diagnosis have been associated
with a 5 to 26 day increase in LOS and a US$24,938
to 115,262 increase in cost per hospitalization as
compared to hospitalizations with the same primary
diagnoses but lacking a diagnosis of aspergillosis.19
Overall, hospitalizations in the United States with
an aspergillosis diagnosis have reportedly been as-
sociated with cost per hospitalization of US$62,426
and total cost of US$633.1 million annually.19
As the current trend toward increased incidence
of fungal infections is unlikely to slow,20 it is im-
portant to gain an understanding of the burden
that such infections may have on society as well as
among distinct at-risk patient populations. While
several studies have examined the burden of ill-
ness associated with fungal infections in the United
States, a comprehensive analysis of the number of
hospitalizations, LOS, cost, and crude mortality as-
sociated with aspergillosis and candidiasis has not
been conducted in Australia. This study focused
on describing these outcomes for aspergillosis and
candidiasis cases overall in Australia. Secondary
analyses were conducted to assess the burden of
fungal infections among groups of patients with
co-morbid pneumonia, other respiratory infections,
cancer, leukemia, and HIV.
Methods
A retrospective analysis of hospital discharge
records from 1995 to 1999 was conducted. The
data were drawn from the National Hospital Mor-
bidity Database (NHMD) compiled by the Australian
Institute of Health and Welfare from data sup-
plied by the State and Territory health authorities.
The NHMD is a collection of electronic conﬁ-
dentialized summary records for admitted pa-
tients dying/discharged from public and private
acute and psychiatric hospitals as well as private
free-standing day hospital facilities in Australia.
The National Health Data Dictionary deﬁnitions
form the bases of the databases, ensuring a high
standard of data comparability. Discharge records
include such information as discharge diagnoses
codes, procedure codes, LOS, patient demograph-
ics (e.g. sex, age group, health insurance status,
state, year, separation mode), and hospital at-
tributes. Data for this analysis were available from
all states and territories with the exception of
Australian Capital Territory and Victoria.
Included in this study were hospitalizations from
acute hospitals with a primary or secondary dis-
charge diagnosis of aspergillosis (ICD-9-CM code:
117.3), pneumonia in aspergillosis (ICD-9-CM:
484.6) (these do not include allergic bronchopul-
monary aspergillosis), disseminated candidiasis
(ICD-9-CM: 112.5), invasive candidiasis (ICD-9-CM:
112.4, 112.81, 112.83, 112.85, 112.89, 112.9, and
771.7), and non-invasive candidiasis (ICD-9-CM:
112.0, 112.1, 112.2, 112.3, 112.82, and 112.84).
The Clinical Classiﬁcation System (CCS), an elec-
tronic tool for clustering patient diagnoses and pro-
cedures into clinically meaningful categories based
on ICD-9-CM, was used to identify co-morbid con-
ditions. Using CCS, ﬁve major disease groups as-
sociated with fungal infections were identiﬁed as
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co-morbidities: pneumonia, other respiratory infec-
tions, cancer, leukemia, and HIV.
Hospital cost was calculated by ﬁrst determin-
ing the average diagnosis-related group (DRG) per
diem cost from the National Hospital Cost Data Col-
lection (NHCDC) 1997—1998 Final Cost Report and
then multiplying that average DRG cost by the ac-
tual LOS reported in NHMD. The NHCDC is a volun-
tary annual collection of hospital cost and activity
data co-ordinated by the Australian Department of
Health and Aged Care. All cost estimates were ad-
justed to reﬂect 1999 Australian dollars.
Trends in the number of hospitalizations, mean
length of hospitalizations, mean costs, and mortal-
ity rates were considered for all cause hospitaliza-
tions and for hospitalizations with aspergillosis and
candidiasis diagnoses separately. T-tests were used
to test whether the estimated growth rates were
signiﬁcantly different from zero. Chi-square tests
were used to test for differences in the mortality
rate between patients with and without a mycotic
infection diagnosis. To assess the burden of these
mycotic infections among patients with various
co-morbid conditions we used the Cox proportional
hazard model for the analysis of the LOS, linear
regression model for cost, and the logistic regres-
sion model for mortality, adjusting for gender,
age group, health insurance status, hospital type
(public/private), and year of discharge. Statistical
signiﬁcance of the parameters of interest was as-
sessed by the t-test. All statistical analyses were
performed using the SAS V6.12 statistical software
(SAS Institute Inc., Cary, North Carolina).
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Figure 1 Number of hospitalizations with aspergillosis and candidiasis diagnoses: 1995—1999.
Results
Trends: 1995—1999
There was an estimated 3.4% (p = 0.007) annual
growth in the number of all cause hospitalizations
from acute hospitals in Australia during the study
period. In comparison, the annual growth rate in
the number of hospitalizations with an aspergillosis
diagnosis was 13.8% (p = 0.08), and in the number
of hospitalizations with a candidiasis diagnosis 3.5%
(p = 0.004) during the same time period (Figure 1).
Although the annual growth in the number of hospi-
talizations with a diagnosis of disseminated or inva-
sive candidiasis was 6.1%, this wasmainly attributed
to random variation rather than a systematic trend
(p = 0.16).
While the mean LOS for all cause hospitalizations
decreased at an annual rate of 3.7% to just under
four days per hospitalization, there were no signif-
icant changes in the mean LOS for hospitalizations
with a diagnosis of aspergillosis (12.2 days) or in-
vasive candidiasis (16.7 days). Contrary to this, the
mean LOS for hospitalizations with disseminated or
non-invasive candidiasis diagnoses increased at an-
nual rates of 13.2% (p = 0.01) and 3.4% (p = 0.02),
from 24.9 to 36.9 and from 11.4 to 12.7 days, re-
spectively (Figure 2).
Similar patterns were observed in the mean
cost of hospitalization. There was no signiﬁ-
cant change in the mean cost of hospitalization
with an aspergillosis diagnosis (p = 0.17). Among
candidiasis hospitalizations, the mean cost of
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Figure 2 Mean length of stay for hospitalizations with aspergillosis and candidiasis diagnoses: 1995—1999.
hospitalizations with a diagnosis of disseminated
candidiasis increased signiﬁcantly at an annual
rate of 23.4% (p = 0.01), from AUS$22,624 to
AUS$46,786 (Figure 3). Although the cost of hospi-
talization with invasive or non-invasive diagnoses
increased at annual rates of 5.7% (p = 0.23) and
3.1% (p = 0.13) respectively, these changes could
not be attributed to systematic trends.
Figure 3 Mean cost of hospitalizations with aspergillosis and candidiasis diagnoses: 1995—1999.
Changes in mortality also could not be attributed
to systematic trends (Figure 4). However, mor-
tality decreased among hospitalizations with an
aspergillosis diagnosis at an annual rate of 10.4%
(p = 0.12), and increased among hospitalizations
with a diagnosis of disseminated or invasive can-
didiasis at annual rates of 9.5% (p = 0.10) and 5.5%
(p = 0.42), respectively. Similarly, mortality among
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Figure 4 Mortality rates among hospitalizations with aspergillosis and candidiasis diagnoses: 1995—1999.
all cause hospitalizations from acute hospitals de-
creased at a 1.9% annual rate (p = 0.14).
Overall burden of aspergillosis and
candidiasis: 1995—1999
We identiﬁed 4583 hospitalizations with an as-
pergillosis diagnosis and 57,758 hospitalizations
Table 1 Outcome characteristics of hospitalizations with aspergillosis and candidiasis diagnoses: 1995—1999.
Outcomes Aspergillosis Disseminated
candidiasis
Invasive
candidiasis
Non-invasive
candidiasis
All
candidiasis
All acute
hospitalizationsa
Number of
hospitalizations
4,583 533 11,885 45,340 57,758 15,967,373
% of total acute
hospitalizations
0.03% 0.003% 0.07% 0.28% 0.36% 100%
Number of
hospitalizations in
public hospitals
3818 458 8602 35653 44713 –—
% of hospitalization
in public hospitals
83.3% 85.9% 72.4% 78.6% 77.4% –—
Mean LOS (days) 12.2 30.7 16.7 12.0 13.12 4.2
Total LOS (days) 55,684 16,361 198,421 542,932 757,714 67,126,141
Mean Cost (1999
$AUS)
$9,334 $33,274 $12,954 $7,694 $9,013 Not available
Total Cost (1999
$AUS in Million)
$42.8 $17.7 $154.0 $348.8 $520.5 Not available
Mortality 8.2% 26.3% 8.6% 7.6% 8.0% 1.2%
Number of deaths 375 140 1,025 3,427 4592 194,466
% of Total deaths 0.19% 0.07% 0.53% 1.76% 2.36% 100%
a All cause hospitalizations from acute hospitals in all states and territories except Australian Capital Territory and
Victoria.
with a candidiasis diagnosis during the study period
(Table 1), representing 0.03% and 0.36%, respec-
tively, of all acute hospital discharges in Australia.
Of all hospitalizations with a candidiasis diagno-
sis, 21.5% were due to the most severe forms of
disseminated or invasive candidiasis.
The mean LOS for hospitalizations with an as-
pergillosis diagnosis was 12.2 days andwas 2.9 times
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longer than the LOS for all cause hospitalizations
from acute hospitals. Overall, hospitalizations with
an aspergillosis diagnosis resulted in 55,684 hospi-
tal days, accounting for over 0.08% of bed days as-
sociated with all cause hospitalizations. The mean
cost of hospitalization with an aspergillosis diag-
nosis was AUS$9,334. The cost of hospitalizations
associated with aspergillosis amounted to AUS$42.8
million during the study period. 8.2% (or 375)
of hospitalizations with an aspergillosis diagnosis
ended in death. Therefore, the unadjusted odds of
a hospitalization ending in death were 7.2 (95% CI:
6.5—8.0) times higher for those with an aspergillo-
sis diagnosis than those without the infection.
Hospitalizations with a candidiasis diagnosis rep-
resented a signiﬁcant burden to the healthcare
system. The mean LOS for hospitalizations with
a candidiasis diagnosis was 3.1 times longer than
the mean LOS for all cause hospitalizations. During
the study period, the total number of bed days
of hospitalizations with a candidiasis diagnosis ac-
counted for 1.1% of all bed days and a total cost of
AUS$520.5 million. Of the 57,758 hospitalizations
with a candidiasis diagnosis, 4592 ended in death,
contributing 2.4% in the total number of all cause
hospitalizations ending in death.
Disseminated candidiasis was associated with
the greatest burden among hospitalizations with a
candidiasis diagnosis. The mean LOS for hospital-
izations with a disseminated candidiasis diagnosis
was 30.7 days, 7.3 times longer than that for all
cause hospitalizations. The mean cost of hospital-
ization was AUS$33,274, for a total of more than
AUS$17.7 million. Of the 533 hospitalizations with
a disseminated candidiasis diagnosis, 140 (26.3%)
ended in death. The unadjusted odds of a hos-
pitalization ending in death were 28.9 (95% CI:
23.8—35.0) times higher for those hospitalized with
a diagnosis of disseminated candidiasis diagnosis
than those without.
The burden of hospitalizations with a diagnosis
of invasive candidiasis was also considerable. The
mean LOS for such hospitalizations was 16.7 days,
with a cost per hospitalization of AUS$12,954, con-
tributing AUS$154 million to healthcare costs. With
a mortality rate of 8.6% the burden was compara-
ble to that of aspergillosis, but considerably higher
than that of all acute hospitalizations (OR: 7.7; 95%
CI: 7.2—8.2).
Outcomes and patients’ co-morbidities
Severe co-morbid conditions are common among
hospitalized patients with fungal infections such as
aspergillosis or candidiasis. In this sample, 84% of
the hospitalizations with an aspergillosis diagno-
sis were coded with at least one of the following
co-morbid conditions: pneumonia (17%), other res-
piratory infections (71%), cancer (15%), leukemia
(9%), and HIV (2%). Similarly, among hospitalizations
with a candidiasis diagnosis other co-morbid condi-
tions included pneumonia (14%), other respiratory
infections (23%), cancer (21%), leukemia (2%), and
HIV (7%).
The LOS among hospitalizations with an as-
pergillosis diagnosis varied signiﬁcantly depending
on patients’ co-morbid conditions. Patients with
co-morbid pneumonia, other respiratory infec-
tions, cancer, or leukemia had signiﬁcantly longer
LOS relative to those without these conditions
(Table 2). The hazard of being discharged was the
lowest (indicating signiﬁcantly longer hospitaliza-
tions) for those with co-morbid pneumonia, being
about 56% of the hazard for those without the
condition. Likewise, cost per hospitalization was
signiﬁcantly affected by patients’ co-morbid con-
ditions. Presence of respiratory infections other
than pneumonia more than doubled the cost per
hospitalization, while pneumonia was associated
with an 88% increase in cost. The odds of dying
during the hospitalization were 3.4 times higher for
patients with co-morbid pneumonia than without
the condition. Similarly, patients with a diagnosis
of cancer or leukemia experienced signiﬁcantly
higher mortality rates than patients hospitalized
without these conditions.
Signiﬁcant differences in the outcomes were ob-
served depending on the type of infection among
hospitalizations with a candidiasis diagnosis. The
estimated hazard of being discharged was the low-
est for hospitalizations with disseminated candidi-
asis, indicating longer LOS than for hospitalizations
with either invasive or non-invasive candidiasis
(Table 2). Relative to those with non-invasive can-
didiasis, cost per hospitalization was more than
twice as high for patients with disseminated can-
didiasis and 22% higher for patients with invasive
candidiasis. The odds of dying during hospitaliza-
tion were 4.0 times higher for those with dissem-
inated candidiasis than those with non-invasive
candidiasis.
After adjusting for type of candidiasis infection
and other individual and institutional characteris-
tics mentioned earlier, co-morbid conditions were
observed to have a signiﬁcant effect on outcomes.
Pneumonia, other respiratory infections, cancer, or
leukemia were associated with longer LOS, the haz-
ard of discharge being 70% to 78% of the hazard
of discharge for a patient without these conditions
(Table 2). Pneumonia and other respiratory infec-
tions were associated with a 55% to 60% increase in
cost per hospitalization, while cancer or leukemia
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Table 2 Estimation of the effect of select co-morbid conditions on the LOS, cost, and mortality for hospitalizations with aspergillosis and candidiasis diagnosesa.
Patients hospitalized with aspergillosis diagnosis Patients hospitalized with candidiasis diagnosis
LOSb Medical cost
parameterc
Mortalityd LOSb Medical cost
parameterc
Mortalityd
Hazard ratio (95% CI) Odds ratio (95% CI) Hazard ratio (95% CI) Odds ratio (95% CI)
Disseminated candidiasise — — — 0.47 (0.42—0.52) 0.83* 4.01 (3.14—5.14)
Invasive candidiasise — — — 0.86 (0.84—0.89) 0.20* 0.86 (0.78—0.94)
Pneumonia 0.56 (0.52—0.62) 0.63* 3.38 (2.67—4.28) 0.73 (0.71—0.76) 0.47* 1.90 (1.72—2.08)
Cancer 0.65 (0.60—0.72) 0.43* 2.15 (1.67—2.77) 0.70 (0.68—0.71) 0.29* 4.49 (4.16—4.84)
Leukemia 0.67 (0.60—0.75) 0.28* 3.51 (2.53—4.86) 0.78 (0.73—0.84) 0.32* 1.88 (1.54—2.29)
Other respiratory infections 0.67 (0.63—0.72) 0.74* 1.24 (0.95—1.62) 0.76 (0.74—0.77) 0.44* 1.30 (1.20—1.41)
HIV 0.92 (0.74—1.15) 0.07 1.61 (0.77—3.33) 1.39 (1.34—1.44) −0.39* 0.88 (0.73—1.06)
a In addition to the indicators of the co-morbid conditions listed above, adjustments were made for gender, age group, health insurance status, hospital type
(public/private), and year of discharge.
b Time to hospital discharge was analyzed using the Cox proportional hazard model. The hazard ratio of being discharged is reported.
c Linear regression analysis of the logarithm of hospital cost. For the indicator variables reported above, the term e, where  refers to the estimated coefﬁcients,
provides the estimated ratio of the expected mean cost for the two groups. For example, among patients hospitalized with aspergillosis diagnosis, e0.63 = 1.88 is
the estimated ratio of the expected mean costs between those with and without co-morbid pneumonia.
d Logistic regression of the probability of dying during the hospitalization.
e The reference group are patients hospitalized with a diagnosis of non-invasive candidiasis.
* T-tests of statistical signiﬁcance based on a p-value <0.001.
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increased cost by 34% to 38%. These co-morbid con-
ditions were associated with signiﬁcantly higher
mortality rates, the highest observed amongst pa-
tients with a cancer diagnosis (OR: 4.5; 95% CI:
4.2—4.8).
Discussion
An upward trend in the number of hospitalizations
with an aspergillosis or candidiasis diagnosis was
observed during the four-year study period. This
ﬁnding is consistent with similar research con-
ducted in other countries.9—11 Improved diagnostic
testing and increased awareness of fungal disease
may have contributed to this increase, however,
the growth in the number of hospitalizations as-
sociated with fungal infections is more likely
due to the ever-expanding population of at-risk
patients.
The increase in the number of hospitalizations
with an invasive candidiasis diagnosis in Australia
during a time when signiﬁcant falls in candidemia
in ICUs have been observed in the US warrants
attention.21 Although infection control practices do
not differ from those in the US, empiric and prophy-
lactic antifungal therapy may not be as common in
the ICU setting in Australia as in other countries, as
there are still questions regarding who is a high-risk
ICU patient.22 For example it has been observed in
clinical practice that more than 50% of candidemia
cases occur in patients in the ICU/high dependency
unit setting; however, the deﬁnition of what con-
stitutes invasive candidiasis is less well established
in the ICU and surgical setting than in haematology
patients. In recent years there has been increasing
awareness of the entity of invasive/deep-seated
candidiasis in this group of patients, due in part
to publications such as those of Blumberg et al.,23
which referred speciﬁcally to risk factors in the
surgical intensive care unit, and Eggimann et al.,24
which referred to a high risk group of surgical pa-
tients with intra-abdominal candidiasis who would
beneﬁt from ﬂuconazole prophylaxis.
The ﬁnding that LOS, cost, and mortality as-
sociated with aspergillosis and candidiasis were
very high in comparison with all cause hos-
pitalizations has also been emphasized else-
where.2,9,12,13,16,17,19,25 Consistent with previous
research, LOS, cost, and mortality differed based
on the type of candidiasis.18,19 Disseminated can-
didiasis was associated with the greatest burden
among hospitalizations with a candidiasis diagno-
sis, and despite increasing treatment options and a
move toward hospital in the home, this burden was
shown to increase over the study period. Although
hospital in the home is gaining ground, patients
under hospital in the home are still classiﬁed as
in-patients and thus were included in LOS. The ris-
ing mortality rate for disseminated candidiasis in
an era of more treatment options is worth noticing.
Although speculative, the rise may be attributed
to the increased awareness of invasive infection in
the complex ICU type of patient, who may expe-
rience higher mortality compared to patients who
were easily identiﬁed in the past as having simpler
cases of candidiasis.
The estimated mortality rate of 8% for pa-
tients with aspergillosis in this study is sub-
stantially low relative to what is shown in the
literature.11 This low ﬁgure is not due to the
potential inclusion of more benign manifesta-
tions of aspergillosis such as allergic bronchopul-
monary aspergillosis, since in addition to being
a rare condition that would not have a large
impact on overall mortality. Care was taken to
exclude such hospitalizations from the admissi-
ble data. However, this low mortality rate could
be attributed to certain NHMD database limita-
tions. For instance, patients who died after dis-
charge were not captured in the hospital-based
ﬁgures. Furthermore, patients may have died dur-
ing subsequent hospitalizations where aspergillo-
sis was not listed as the primary or secondary
diagnosis.
Lack of data from the state of Victoria may have
had an impact on the overall numbers. An earlier
study found that candidemia occurrence in the
state of Victoria was similar to that of New South
Wales and that the rate of candidemia was similar
in the hospitals surveyed in four different states.26
Furthermore, the pattern of species detected dif-
fered slightly between states, but C albicans was in
every state the predominant species. Lack of data
from the Australian Capital Territory (the least
populous state) is not expected to affect overall
measures. Other limitations of the database in-
clude possible inaccuracies due to miscoding, mis-
classiﬁcation, and missing or incomplete capture
of cases; an absence of detailed clinical data for
any examination of clinical outcomes; and lack of
data on individual patients for per patient anal-
yses. All of these limitations warrant a cautious
interpretation of the results. However, despite
these shortcomings of the NHMD, which are com-
mon among hospital databases,27 the magnitude
of readily available information that it provides
makes it an efﬁcient data source for this burden of
illness study.
As this study evaluated only hospitalized pa-
tients, it may not capture the entire burden of fun-
gal infections to society. This study also is limited
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to infections caused by aspergillosis and candidi-
asis. Although these two pathogens represent the
majority of fungal infections, infections due to
other fungal species may result in an additional
burden to society.
This study provides a macro view of the burden
of hospitalizations of patients with fungal infec-
tions in Australia. Additionally, since this study
was based on a retrospective database review, it
is free of the protocol-driven biases that are of-
ten present in prospective clinical studies. Future
research should evaluate treatments in different
sub-populations of aspergillosis and candidiasis pa-
tients to determine optimal therapeutic approaches
for various host groups in terms of outcomes
and costs. A more in-depth epidemiological study
could provide additional insight into the trends
by breaking the Candida infections into responsi-
ble species, information that was not available in
the NHMD.
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